SynthesisFrontiers in medicine2025
Prevalence and clinical characterisation of thyroid dysfunction in COPD: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of COPD is increasing annually, accompanied by a growing number of complications and organ function abnormalities. Thyroid dysfunction is prevalent among patients with chronic obstructive pulmonary disease (COPD). Updated evidence is needed to complement previous systematic reviews on this topic to provide best practice. Methods: The EMBASE, Web of Science, Cochrane and PubMed databases were searched for articles containing the keywords "COPD" and "thyroid dysfunction" (PROSPERO CRD42024592606). Eligibility screening, data extraction and quality assessment of retrieved articles were performed independently by two reviewers. Meta-analyses were performed to determine the prevalence of thyroid dysfunction in patients with COPD. Regression analyses were used to explore sources of heterogeneity. The clinical features of COPD combined with thyroid dysfunction were clarified by comparing the age, sex (percentage of males), BMI, smoking index, Forced Vital Capacity (FVC%), Forced Expiratory Volume in One Second (FEV1%), partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2), and albumin in patients with and without thyroid dysfunction. The differences in the prevalence of thyroid dysfunction between stable and acute exacerbations in COPD were also compared. Results: Twelve studies were included, with an overall prevalence of 42.1% (95% CI, 31.8-52.9). The most common type of thyroid dysfunction in COPD was non-thyroidal illness syndrome (NTIS) in 45.3% (95% CI, 22.3-68.3). There was no difference in the prevalence of dysfunctions between stable and acute exacerbations of COPD. Patients in the thyroid dysfunction group in COPD had lower PCO2 and albumin and higher FEV1%. Conclusion: Thyroid dysfunction has a high prevalence among patients with COPD, with NTIS being the most common. Thyroid dysfunction in COPD may affect lung function and lead to decreased albumin. Patients with COPD should be screened for thyroid function, and attention should be paid to the clinical features of this group of patients with thyroid dysfunction to facilitate better identification and management. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/myprospero, PROSPERO ID (CRD42024592606).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.